In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, down 1.35% from the previous day. The stock has risen by 6.24% in the past month, outperforming the Medical sector and the S&P 500. Analysts predict an EPS of $4.09 and revenue of $2.63 billion in the upcoming earnings disclosure.

Investors should pay attention to recent analyst estimates for Vertex Pharmaceuticals, as they indicate short-term business patterns. Positive estimate adjustments reflect optimism about the company’s profitability. The Zacks Rank system, with a current rating of #3 (Hold) for VRTX, has shown an average annual return of +25% for #1 ranked stocks since 1988.

Vertex Pharmaceuticals is trading at a Forward P/E ratio of 27.77, higher compared to the industry average. With a PEG ratio of 2.17, the stock is expected to have strong earnings growth. The Medical – Biomedical and Genetics industry, where Vertex operates, holds an average PEG ratio of 1.97 and a Zacks Industry Rank of 83.

Zacks experts have identified a little-known chemical company with significant upside potential. The company has seen a 65% increase in stock price over the past year and has strong earnings estimates for 2022. Retail investors are advised to consider this stock, which could outperform recent top performers like Boston Beer Company and NVIDIA.

Read more at Nasdaq: Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts